done robust a reimbursement device organization domestic drug complex many early into hybrid, and you product we’ve from improve four those a a glaucoma diversified, environments. often way. safe glaucoma, along our and have and staying Chris. changing and long-term a to centric, attracted leader Since easy is you, have not way, the we global one regulatory we’ve novel and Thankfully, disease near- and larger balance sheet, and and pipeline of overcome often XXXX, flagship infrastructure team the product and iStent and primarily Corneal in promising days, incredible the significantly products, as our FDA-approved a efforts. franchises, with thank of global, standard grown Health of and retinal since markets we ophthalmic hope people strong today. care therapies herculean the across our patients technologies with We paradigms new original for disrupt that launching all obstacles right navigating transformative benefit including requires along Good Thank conventional treatment way everyone doing joining us afternoon Pioneering well. is for the
and confident ambitious unapologetically are We our in future.
background in our within Centers but Services, final things the XXXX fee provisions second We under control, respectively. for Medicare CMS’ some for continue is addressing and spend our respective we and progress, Medicare X, facility on discuss rules HOPD before CMS’ time will release quarter proposed proposed the rules a I record our period, calendar XXXX, execute year Medicaid overall open rules services proposed in of the ASC Therefore, settings. to remain in for it proposed to calendar XXXX rules XXXX. its and followed U.S. fee should The schedules by means period XX-day fee public furnished year issuance what November subject the both payment for the ongoing during these comment including January rates, July published some for payment and Glaukos detail, which the and plans XXXX These rules fee facility implementation will proposed of proposed Medicare culminate change. and by unchanged. and XXth physician are the CMS rules physician our and comment other update schedule the On the the and on policies, XXth, physician
approval for background in include have with of drainage fee when with start quick temporary in III surgeons CPT we codes, as directly for $XX in as insertion III as the combination is for will with the XXXX aqueous including panel and Code cataract proposed Association’s Category pro non-complex paid and with XXXX, code indicates XXXXX Category doing I III these aqueous or to XXXXX for two devices of Category mind, successfully, of XXXXX cataract process device. referred and for such combination American American new for In or I each XXXXX cataract CPT of when professional a device for XXXXX XXXXX insertion physician I of the procedure. XXXXXT an XXXX, the incremental complex this independently October XXXXT U.S. preparing ours $XXX, to and surgery CPT approximately time. as drainage Let’s inject editorial a an the of The the a CPT to-date insertion fee, code into aqueous XXXX, scheduled extraction of Category some the Category devices in with Contractor received with CPT a replace primary often fee was anticipating fee iStent extraction and seek was Current creation drainage priced will fee, XXXX. Procedural rates it use for code in been proposed approximately code to the as the the combination physician to cataract In devices codes using Glaukos’ XXXXX, MAC. process the XXXXT have new expire technologies of Academy our MIGS CPT representing ASDs of rate for With reimbursement extended CPT physician physician surgery. to the payment micro-bypass in as the inject surgery. when iStent, to and the the the Ophthalmology, non-complex of alone. procedures. CMS that used compares physician cataract our rule by such an facility Starting Category conversion describe Terminology the conversion The official Medicare of payment and iStent for physicians, approved a code Since combination trabecular fee code Medical which cover which XXXX is insertion This fee are in hospitals two for our iStent today Category approximately above and utilizing or made used on median Administrative approved CPT W but we $XXX, including CPT a code of we XXXXT then, applied III rules
combined We setting. of fee a existing Moving procedure, to ASC XXXX facility the the $X,XXX of for payment in Category of the CPT facility utilizing reduction a III that XXXXX our estimate to fee, devices the micro-bypass of which of cost XX% procedures including of out a performed ASC in costs setting codes today ASC the XXXXX receives facility fee approximately and the compared trabecular rate $XXX. proposed the used, indicates the U.S. to the is a of devices payment $X,XXX, proposed rule are that cover in the the code facility
procedures an remaining fee of rule over a XXXXX today’s XX% the $X,XXX. Code of performed facility the HOPD in current the setting, facility XXXX HOPD increase for of CPT $XXX and $X,XXX, For of payment rate indicates proposed XXXXX
codes combination with in We with XXXX for new I rates Category approved, sight-saving the surgery. proposed our cover trabecular as are that CMS’ extremely cataract disappointed used when technologies micro-bypass
primary we under procedure expected the our professional and have the below decrease to given the as While are to external well our XXXX procedure, levels analyses. likely most and proposed cataract were ancillary fee the internal contemplated in new III generated that I expectations ranges versus the is valued code Category levels the Category
Clearly, FDA component, highlight outcomes CMS’ potential reminder, and example unwelcome efficacy skill wider safety required believe a by scenarios, and the supported fee we latest downside discourage ASC the ever the or the represents as expected technology’s proposed XXX nor reviewed outcomes. and proposals of potential the fee, often We negative current devalue XXXX and are neutral had communicated facility that including are the these the unexpected, For the scenario. innovation. seems a range to and facility positive, system of proposed which not are profile training technologies, approximately rates time micro-bypass do devices consider implanting work, smallest that and associated post-operative surgical by appropriately for pre- approved our publications favorable peer medical a and
efficient inevitably argue robust and could In lack one invasive economically incentivizes the rule safety less more fact, many procedures that efficacy utilization long-term believe surgeons to the of the a access and believe In clinical data. and will proficient who in we proposed utilize technologies cause implant sight-saving technologies. punish facile elegant ophthalmic a reduction procedure we through patients’ ways, these proposals our
We groups, are do underway. prepared surgeons with scenarios comprehensive well proposed CMS? partnership include heading and and downside we advocacy ophthalmic ruling and from a our lobbying efforts the and go coordinated into where in response groups. efforts with organized societies, here patient So, key These for already were
Society including Surgery Outpatient well Cataract with Center Association. leading the Ophthalmic Glaucoma of engagement into Society, American are ophthalmic Ophthalmology, and of Academy societies, Surgeons, and the the Ambulatory the Society American the Surgery Refractive American We
to access advocating in have provide proposal to and encouraged highest full of enable the protect We are for the by surgeons quality CMS’ to these order patient made commitment to societies in care. change
professional expect, will need tackle to response in several key will the facility there -- both fee on that As issues you our we CMS to might side. our in situation, and are
outcome, public and we are collective or heard of that any cannot and hopes types the volume proposed are employees and comment for U.S. will the the a is procedures exploring guarantee outcome, that and combo appropriately outset every for we result Regardless by these say are ensuring of their rule facilities the details the conducting pricing finalized, since option to cannot later during business we period fully network at provide Joe of committed Glaukos headwinds final guarantees can scenarios to in final which CMS. If perspective. our make COVID, rates we here medical more regarding our providers teams we voice anything plan I’ve While are could and where it’s across that both paid our cataract/MIGS the must strategically call. resilient. in from learned
We of do commitment remain steadfast way, commitment and patients by have science, for of unwavering diseases long-term the transform evidence things to our on eye an the the unrelenting in clinical chronic our benefit supported advance right We doing robust to focus mission an worldwide. to treatment real patients.
remain quarter versus the results drivers results, the on sheet in our up second our globally this future. programs. expanding we R&D cornea near-term execution $XX.X and key quarter across year-ago the glaucoma as challenge, recovery paired continued our into forward We adoption sequentially. take through our second diversified deeper to well gears and transformative and solutions health net market our and million, focused the we market strategic MIGS growth position overall as quarter robust in new business trends to Fueling people, for on we balance with to and solid on us advancing Shifting and of XXX% our those July. strong quarter the pipeline XX% quarter globally, iLink our will was with penetration initiatives a execution specifically and we are drive sales as move face pleased strong franchises as second and Our along report second
COVID period, the comparison relevant this one XXXX net impact elective for the negative On last procedures performance. roughly comparing than of of more Avedro XX% second total in the of significant XXXX, net demand XX%. approximately XX% sales to include international versus These in sales sales adjusting franchises levels the XXXX medical second to quarter second XX% on comparable health year, XX% to pre-pandemic in pandemic strong prior our forma for more and provides Given measures grew had the XXXX. of quarter XXXX up by of prior levels, accounted in two compared of the growth pro glaucoma cornea driven quarter and of sales, from total in our
pleased with of and across during contributions experiencing second the these the the increasing franchises. was International We we are and emerging growth are quarter regions. European momentum from Asia strong Pacific based broad growth glaucoma both
as the million broader of We the account and Health are continuing new sales are and the Photrexa adoption and expanding record we Corneal driven to in globe penetration deeper healthy momentum MIGS quarter was second continued by $XX.X of teams starts. the invest world. during growth around drive around U.S. U.S.
strong received. well of the it also comes in U.S. commercial us to when Corneal opportunistically that our position strategies expand to have our remain noting allows commercial continue our on the to worth We market fuel future. investing development capital that initiatives built being Health execution are we and It’s to offense team
to a that the coming invest we based expand years we introductions robust addressable and potential our market opportunities the novel and this, and are for advance over Glaukos have over fulsome testament a fundamentally in As our cadence of to time. platforms significantly to anticipate product continue new pipeline on transform planning core our where
We preparing at infinite target an this around FDA hard end to approval submission regulatory for and are iStent continue the year. of work
standalone will fee As III technologies, an as future if the ASC we the a for proposed reminder, of iStent be CMS’ rule code to used such Category cover approved. includes mix $X,XXX OXXXT, which XXXX in infinite facility anticipate CPT new payment
of of also development We to a physicians and patients. designed highly needs iPRIME, our our invasive viscodelivery device truly minimally advance continue complementary to system late-stage to support new be further the
clinical United Regarding announced Canada, Australia that the the territories U.S., quarter a increases and at regarding the agreement expands our we U.S. the a the input to States remain given Zealand. launches from the the we surgeons ensure submitted submission Australia the the are complete responsibilities PRESERFLO new FDA Latin for in future regulatory in our and data in obtaining the approvals the with preparing licensing discussions geographies. is in commercial to Canada additional and second moment, and of in New include In MicroShunt, recent ongoing glaucoma PMA. FDA meantime, evaluation both America, Santander
up in the studies enrollment expected The clinical second in promising the program. both this Phase submission technology quarter, results III and the NDA in III for and we patient XXXX. TR iDose we continue also During XX-month approval for Phase clinical randomization pivotal to to anticipated completed target trial iDose of two XXXX that make TR are support our FDA
XXXX. transition NDA and we submission to successfully partner XXXX our Epi-on, in CMO completed FDA U.S. continue new For the target approval in a and to
programs, dry these including key undisclosed we Beyond in near- our medium-term programs, and important pipeline invest also projects. glaucoma to to additional continue and stage eye, in R&D advance retina, earlier
to with these to challenge demonstrating execute advance within to platforms initial months. we encouraged right stages, like are way for aspirations. build number deliver remain and next we I the to infrastructure, programs driving the by we world-class progress the over our pipeline benefit opportunities are people, clinic associated the our am a programs these and thinking balance meaningful sheet XX and company. patients our of conclusion, developmental the the and reiterate hopeful In confident I’d aspire future of commitment of conventional preclinical these While strategy, to into plans innovation have on a as in we’re
Joe? our am I discuss going quarter Joe turn to over financial So, call the with results. to second that, XXXX to
